Combined Application of Lenalidomide and Desamethasone in the Palliative Therapy of Patients With Multiple Myeloma
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Multiple Myeloma
Both
Multiple Myeloma
Trial Information
Combined Application of Lenalidomide and Desamethasone in the Palliative Therapy of Patients With Multiple Myeloma
Inclusion Criteria:
- Patients with multiple myeloma with at least one previous therapy.
- 18 years or older
- Signed, written informed consent
Exclusion Criteria:
- Pregnancy or nursing
- All other exclusion criteria listed in SmPC (summary of product characteristics)
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Time to progression (TTP)
Outcome Time Frame:
maximum 3 years per Patient
Safety Issue:
No
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
IOM-0810
NCT ID:
NCT00911105
Start Date:
May 2009
Completion Date:
May 2014
Related Keywords:
- Multiple Myeloma
- Multiple Myeloma
- Non-interventional study
- Lenalidomide
- Dexamethasone
- Observational
- Time to progression
- Clinical routine
- Germany
- Plasmacytoma
- Multiple Myeloma
- Neoplasms, Plasma Cell
Name | Location |
|---|
